News
-
-
PRESS RELEASE
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop novel psilocin prodrug from Enveric Biosciences for neuropsychiatric indications, utilizing microdosing to minimize hallucinogenic effects of psychedelic compounds -
-
PRESS RELEASE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. showcases women's health trials and upcoming data presentation on Phase 2A trial of MB22001 for Major Depressive Disorder. Company pioneering microdosing LSD for mental health conditions -
-
PRESS RELEASE
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
MindBio announces successful completion of Phase 1 and Phase 2a Clinical Trials for MB22001 in treating Major Depressive Disorder. Company plans dual listing on senior exchange -
-
-
-
PRESS RELEASE
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
MindBio's sleep research using MB22001 published in Nature's Translational Psychiatry journal. Research indicates improved sleep quality & duration after microdosing, advancing treatment for depressive disorders globally
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
abrdn Income Credit Strategies Fund Announces Update and Tentative Closing Date for Acquisition of Assets From First Trust High Income Long/Short Fund
-
Electric Royalties Announces Interest Conversion Under Convertible Credit Facility
-
Pfister Faucets' American Plumber Stories Docuseries Wins Three Telly Awards
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business